Miklos Egyed

8PUBLICATIONS
32CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical infection agents (incl. prions)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 16, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.

|Apr 08, 2025
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak

|Apr 21, 2024
Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.

Egyed Miklos, Tóth Peter Oliver, Kellner Adam

|Feb 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Stephen T Oh, Srdan Verstovsek, Vikas Gupta

|Oct 30, 2023
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.

Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano

|May 19, 2023
A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register.

Eva Karadi, Peter Dombi, Viktoria Gyorine Korom

Pageof 2

Frequent Collaborators

2 joint publications

Wojciech Jurczak

1 joint publications

Rajnics Peter

1 joint publications

Eva Karadi

1 joint publications

Peter Dombi